Sinovac Biotech (FRA:SVQ) FCF Margin % : 29.64% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sinovac Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sinovac Biotech's Free Cash Flow for the six months ended in Dec. 2023 was €83.7 Mil. Sinovac Biotech's Revenue for the six months ended in Dec. 2023 was €282.3 Mil. Therefore, Sinovac Biotech's FCF Margin % for the quarter that ended in Dec. 2023 was 29.64%.

As of today, Sinovac Biotech's current FCF Yield % is -9.06%.

The historical rank and industry rank for Sinovac Biotech's FCF Margin % or its related term are showing as below:

FRA:SVQ' s FCF Margin % Range Over the Past 10 Years
Min: -78.65 Med: -0.3 Max: 75.52
Current: -9.48

During the past 13 years, the highest FCF Margin % of Sinovac Biotech was 75.52%. The lowest was -78.65%. And the median was -0.30%.

FRA:SVQ's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -144.01 vs FRA:SVQ: -9.48

Sinovac Biotech FCF Margin % Historical Data

The historical data trend for Sinovac Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech FCF Margin % Chart

Sinovac Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

11.56

68.87

75.52

-78.65

-9.30

Sinovac Biotech Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															71.21	-89.71	-30.86	-94.68	29.64

Competitive Comparison of Sinovac Biotech's FCF Margin %

For the Biotechnology subindustry, Sinovac Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinovac Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's FCF Margin % falls into.

Sinovac Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sinovac Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-38.231	/	411.063
	=	-9.30 %

Sinovac Biotech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	83.669	/	282.312
	=	29.64 %

Sinovac Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (FRA:SVQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (FRA:SVQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Sinovac Biotech (FRA:SVQ) Headlines

No Headlines